Search research articles
Contact Us
Filters
Showing results (221-230 of 247) with videos related to
Page
of 25
Sort By:
Nature Communications
|
November 12, 2015
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda, Regina Mayor, Charlotte K Y Ng, et al.
Cell Reports. Medicine
|
May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancers
Aung Naing, Xiqi Li, Qi Wang, et al.
Cancer Cell
|
October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
The New England Journal of Medicine
|
February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer
Alison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Cancer Discovery
|
August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D Engstrom, Ruth Aranda, Laura Waters, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trials
Alice Rossi, Irene Braña, Maria Vieito, et al.
The Journal of Clinical Investigation
|
June 3, 2025
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models
Mei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, et al.
The Journal of Clinical Investigation
|
September 24, 2025
USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer
Nishi Kumari, Sarah Ce Wright, Christopher M Witham, et al.
Nature Communications
|
March 22, 2024
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 247) with videos related to
Sort By:
Page
of 25
Nature Communications
|
November 12, 2015
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda, Regina Mayor, Charlotte K Y Ng, et al.
Cell Reports. Medicine
|
May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancers
Aung Naing, Xiqi Li, Qi Wang, et al.
Cancer Cell
|
October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
The New England Journal of Medicine
|
February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer
Alison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Cancer Discovery
|
August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D Engstrom, Ruth Aranda, Laura Waters, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2026
Evolving landscape of targeted therapies in early phase clinical trials
Alice Rossi, Irene Braña, Maria Vieito, et al.
The Journal of Clinical Investigation
|
June 3, 2025
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models
Mei-Kuang Chen, Hirohito Yamaguchi, Yuan Gao, et al.
The Journal of Clinical Investigation
|
September 24, 2025
USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer
Nishi Kumari, Sarah Ce Wright, Christopher M Witham, et al.
Nature Communications
|
March 22, 2024
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, et al.
Page
of 25